BioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2024 Financial Results Conference Call. All participants are present in listen-only mode. Foll ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2024 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions-and-answers after our management's pr ...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Participants Kelly Shi - Jefferies Edward Tenthoff - Piper Sandler Mark Fromm - TD Cowen Robert Driscoll - Wedbush Michael ...

Core Viewpoint - Immuneering has appointed Dr. Igor Matushansky as Chief Medical Officer to lead clinical activities and oversee the ongoing Phase 2a study of IMM-1-104 in pancreatic cancer, with plans for a pivotal Phase 3 trial in the future [1][2] Company Overview - Immuneering is a clinical-stage oncology company focused on developing and commercializing therapies that are more effective and better tolerated for cancer patients [3] - The lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK aimed at improving tolerability and expanding indications for RAS-driven tumors, including pancreatic cancer [3] Clinical Development - The ongoing Phase 2a trial of IMM-1-104 is designed to provide first-line pancreatic cancer patients with a new treatment option that is more effective and better tolerated than current standard care [2] - The company plans to present updated data from the Phase 2a trial in Q2 2025 [1] Leadership Experience - Dr. Matushansky brings extensive oncology drug development experience, having previously served as Chief Medical Officer at Sail Biomedicines and held senior roles at Ipsen Pharmaceuticals and Hookipa Pharma [2] - His background includes overseeing the completion of NAPOLI-3, which led to the approval of NALIRIFOX for first-line pancreatic cancer [2]

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, identifying patterns and aiding in informed decision-making. Within this domain, digital pathology plays a crucial role, leveraging AI algorithms to detect cancerous cells, classify tumor subtypes and enhance patient outcomes. Among its key focus areas, AI-powered automated image analysis and biomarker identification stand out as major advancements.AI/ML in precision oncology has garner ...

Core Insights - Medigene AG and EpimAb Biotherapeutics have entered a strategic co-development agreement to create off-the-shelf T cell receptor-guided T Cell Engagers (TCR-TCEs) aimed at treating immune-related disorders, particularly solid tumors [1][2]. Company Overview - Medigene AG specializes in immuno-oncology, focusing on developing TCR-guided therapies that effectively eliminate cancer. The company utilizes its End-to-End Platform to generate optimal TCRs characterized by sensitivity, specificity, and safety [4]. - EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company that develops multispecific antibodies, leveraging proprietary platforms to advance a unique pipeline of preclinical and clinical assets targeting cancer [5]. Collaboration Details - The collaboration combines Medigene's TCR generation capabilities with EpimAb's CD3 antibody and T-FIT platform, aiming to produce bispecific therapeutics that offer targeted immune responses while minimizing off-target effects [2][3]. - Both companies will equally own the TCR-TCE constructs developed through this partnership, emphasizing a shared commitment to innovation in cancer treatment [2][3]. Market Potential - The bispecific therapy market is projected to grow at a compound annual growth rate (CAGR) of 40.9% from 2023 to 2030, with an estimated market value exceeding USD 80 billion by 2030, indicating significant potential for improving patient outcomes in cancer treatment [4]. - Over 5 million cancer patients globally face low five-year survival rates, highlighting the urgent need for innovative therapies like bispecific TCR-TCEs that utilize the immune system to target and eliminate cancer cells [3]. Technology Insights - TCR-TCEs represent a novel immunotherapy approach that utilizes the specificity of TCRs to direct T cells towards cancer cells, allowing for a broader range of targetable antigens compared to conventional antibodies [6][8]. - The TCR-TCEs activate the patient's T cells through binding to cancer-specific antigens, leading to the release of cytokines and cytotoxic molecules that facilitate the destruction of cancer cells [8][9].

Gilead Sciences (GILD) Conference February 14, 2023 11:20 AM ET Speaker0 Great. Good morning, everybody, and thank you for joining us for this next session with Gilead. On behalf of SVB Securities, I'm very pleased to host Murdad Parsi from the company to discuss the company's pipeline prospects. And so, Murdad, it would be great for you to maybe just comment at a, you know, very briefly at a high level about the position you see Gilead in today versus, you know, obviously where it was even just nine to twe ...